13 September 2022 | The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review
| Stolbrink, M; Thomson, H; Hadfield, RM; et al. |
14 July 2022 | Best practice management of patients with chronic obstructive pulmonary disease: A case-based review
| Vega-Olivo, M; Halpin, DMG; Han, MK; et al. |
1 July 2022 | Blood eosinophils and chronic obstructive pulmonary disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review
| Singh, D; Agusti, A; Martinez, FJ; et al. |
24 September 2022 | Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting
| Halpin, DMG; Rothnie, KJ; Banks, V; et al. |
20 July 2022 | Comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: A network meta-analysis
| Ismaila, AS; Haeussler, K; Czira, A; et al. |
2 September 2022 | Correction to: Comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: A network meta-analysis.
| Ismaila, AS; Haeussler, K; Czira, A; et al. |
25 October 2022 | Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: The INTREPID trial
| Halpin, DMG; Kendall, R; Shukla, S; et al. |
7 September 2022 | Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
| Bourdin, A; Virchow, JC; Papi, A; et al. |
23 May 2023 | Dupilumab reduced severe exacerbation rates and improved pre-bronchodilator Fev 1 in patients with moderate-to-severe asthma regardless of exacerbation history of 蠅1, 蠅2, or 蠅3 prior exacerbations: Liberty Asthma Traverse
| Maspero, JF; Corren, J; Katelaris, C; et al. |
1 October 2022 | Dupimulab reduced exacerbations and improved lung functions in patients with moderate-to-severe asthma and prior exacerbations: Liberty Asthma Traverse study
| Corren, J; Castro, M; Maspero, JF; et al. |
15 August 2022 | Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
| Thompson, PJ; Criner, GJ; Dransfield, MT; et al. |
17 July 2022 | Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis
| Ismaila, AS; Haeussler, K; Czira, A; et al. |
21 April 2023 | Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study
| Halpin, DMG; Dickens, AP; Skinner, D; et al. |
1 November 2022 | Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.
| Stolbrink, M; Chinouya, MJ; Jayasooriya, S; et al. |
1 December 2022 | Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries
| Rylance, S; Bateman, ED; Boulet, L; et al. |
15 September 2022 | Lung health for all: Chronic obstructive lung disease and World Lung Day 2022
| Halpin, DMG; Vogelmeier, CF; Agusti, A |
8 December 2022 | Mortality risk and serious cardiopulmonary events in moderate-to-severe COPD: Post hoc analysis of the IMPACT trial
| Wells, JM; Criner, GJ; Halpin, DMG; et al. |
15 November 2022 | Pharmacotherapy and mortality in chronic obstructive pulmonary disease.
| Halpin, DMG; Martinez, FJ |
1 April 2023 | A response to: Letter to the editor regarding "Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis"
| Ismaila, AS; Haeussler, K; Malmenäs, M; et al. |
10 April 2023 | Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
| Bousquet, J; Melén, E; Haahtela, T; et al. |